| Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors J Strosberg, G El-Haddad, E Wolin, A Hendifar, J Yao, B Chasen, E Mittra, ... New England Journal of Medicine 376 (2), 125-135, 2017 | 2870 | 2017 |
| The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy R Srirajaskanthan, I Kayani, AM Quigley, J Soh, ME Caplin, J Bomanji Journal of Nuclear Medicine 51 (6), 875-882, 2010 | 394 | 2010 |
| The UK‐PBC risk scores: derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis M Carbone, SJ Sharp, S Flack, D Paximadas, K Spiess, C Adgey, ... Hepatology 63 (3), 930-950, 2016 | 382 | 2016 |
| Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international … HIT trial collaborators lancet, 2020 | 319 | 2020 |
| International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways HJ Cordell, Y Han, GF Mells, Y Li, GM Hirschfield, CS Greene, G Xie, ... Nature communications 6 (1), 8019, 2015 | 315 | 2015 |
| Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial M Pavel, DJ Gross, M Benavent, P Perros, R Srirajaskanthan, ... Endocrine-Related Cancer 25 (3), 309-322, 2018 | 134 | 2018 |
| Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score M Carbone, A Nardi, S Flack, G Carpino, N Varvaropoulou, C Gavrila, ... The Lancet Gastroenterology & Hepatology 3 (9), 626-634, 2018 | 133 | 2018 |
| the investigation and management of gastric neuroendocrine tumours R Basuroy, R Srirajaskanthan, A Prachalias, A Quaglia, JK Ramage Alimentary pharmacology & therapeutics 39 (10), 1071-1084, 2014 | 133 | 2014 |
| the investigation and management of rectal neuroendocrine tumours R Basuroy, A Haji, JK Ramage, A Quaglia, R Srirajaskanthan Alimentary pharmacology & therapeutics 44 (4), 332-345, 2016 | 104 | 2016 |
| An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs HJ Cordell, JJ Fryett, K Ueno, R Darlay, Y Aiba, Y Hitomi, M Kawashima, ... Journal of hepatology 75 (3), 572-581, 2021 | 101 | 2021 |
| The Glasgow Blatchford scoring system enables accurate risk stratification of patients with upper gastrointestinal haemorrhage R Srirajaskanthan, R Conn, C Bulwer, P Irving International journal of clinical practice 64 (7), 868-874, 2010 | 96 | 2010 |
| Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies R Srirajaskanthan, J Watkins, L Marelli, K Khan, ME Caplin Neuroendocrinology 89 (3), 308-314, 2009 | 96 | 2009 |
| Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study J Strosberg, PL Kunz, A Hendifar, J Yao, D Bushnell, MH Kulke, RP Baum, ... European Journal of Nuclear Medicine and Molecular Imaging 47, 2372-2382, 2020 | 91 | 2020 |
| Lymphogranuloma venereum proctitis masquerading as inflammatory bowel disease in 12 homosexual men S Soni, R Srirajaskanthan, SB Lucas, S Alexander, T Wong, JA White Alimentary pharmacology & therapeutics 32 (1), 59-65, 2010 | 82 | 2010 |
| A review of thymic tumours R Srirajaskanthan, C Toubanakis, M Dusmet, ME Caplin Lung Cancer 60 (1), 4-13, 2008 | 74 | 2008 |
| Update on pathophysiology, treatment, and complications of carcinoid syndrome D Clement, J Ramage, R Srirajaskanthan Journal of oncology 2020 (1), 8341426, 2020 | 73 | 2020 |
| Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015 TSE Genus, C Bouvier, KF Wong, R Srirajaskanthan, BA Rous, DC Talbot, ... British journal of cancer 121 (11), 966-972, 2019 | 72 | 2019 |
| Long‐term results of patients with malignant carcinoid syndrome receiving octreotide LAR C Toumpanakis, J Garland, L Marelli, R Srirajaskanthan, J Soh, P Davies, ... Alimentary pharmacology & therapeutics 30 (7), 733-740, 2009 | 67 | 2009 |
| Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial SA Taylor, S Mallett, S Ball, S Beare, G Bhatnagar, A Bhowmik, P Boavida, ... The Lancet Respiratory Medicine 7 (6), 523-532, 2019 | 65 | 2019 |
| Delays and routes to diagnosis of neuroendocrine tumours R Basuroy, C Bouvier, JK Ramage, M Sissons, R Srirajaskanthan BMC cancer 18, 1-8, 2018 | 63 | 2018 |
Dr Martyn CaplinProfessor of Gastroenterology and Neuroendocrine Tumour Biology在 ucl.ac.uk 的电子邮件经过验证
